Cargando…

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium

PURPOSE: In 75% of ovarian cancer patients the tumor mass is completely eradicated by established surgical and cytotoxic treatment; however, the majority of the tumors recur within 24 months. Here we investigated the role of circulating tumor cells (CTCs) indicating occult tumor load, which remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obermayr, Eva, Bednarz-Knoll, Natalia, Orsetti, Beatrice, Weier, Heinz-Ulrich, Lambrechts, Sandrina, Castillo-Tong, Dan Cacsire, Reinthaller, Alexander, Braicu, Elena Ioana, Mahner, Sven, Sehouli, Jalid, Vergote, Ignace, Theillet, Charles, Zeillinger, Robert, Brandt, Burkhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739744/ https://www.ncbi.nlm.nih.gov/pubmed/29290959 http://dx.doi.org/10.18632/oncotarget.22468

Ejemplares similares

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
por: Obermayr, Eva, et al.
Publicado: (2010)

tRNA(GlyGCC)-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression
por: Panoutsopoulou, Konstantina, et al.
Publicado: (2021)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2015)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
por: Niemi, Riikka Johanna, et al.
Publicado: (2018)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
por: Lambrechts, Sandrina, et al.
Publicado: (2015)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a6uvps0oocvkhirumemmsntfeg